Sekar Kathiresan's Insider Trades & SAST Disclosures
Sekar Kathiresan's most recent trade in Verve Therapeutics Inc was a trade of 488,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 8, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Sekar Kathiresan.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2025 | 488,000 | 488,000 | - | - | Stock Option (right to buy) | |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2025 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2025 | 120,000 | 120,000 | - | - | Restricted Stock Units | |
|
Verve Therapeutics Inc
|
Kathiresan Sekar | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 04 Dec 2024 | 30,000 | 110,997 | - | 0 | Common Stock | |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 04 Dec 2024 | 30,000 | 323,508 | - | 0 | Common Stock | |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.87 per share. | 28 Jun 2024 | 30,000 | 351,128 | - | 2.9 | 86,100 | Common Stock |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2024 | 30,000 | 215,308 | - | - | Stock Option (right to buy) | |
|
Relay Therapeutics Inc
|
Sekar Kathiresan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 102,225 | 102,225 | - | - | Stock Option (Right to Buy) | |
|
Verve Therapeutics Inc
|
Kathiresan Sekar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 526,000 | 526,000 | - | - | Stock Option (right to buy) | |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 132,000 | 132,000 | - | - | Restricted Stock Units | |
|
Relay Therapeutics Inc
|
Sekar Kathiresan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 66,055 | 66,055 | - | - | Stock Option (Right to Buy) | |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2023 | 550,200 | 550,200 | - | - | Stock Option (right to buy) | |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.39 per share. | 03 Oct 2022 | 50,000 | 367,839 | - | 1.4 | 69,500 | Common Stock |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 50,000 | 138,995 | - | - | Stock Option (right to buy) | |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 33.02 per share. | 03 Oct 2022 | 28,911 | 338,928 | - | 33.0 | 954,517 | Common Stock |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 34.13 per share. | 03 Oct 2022 | 11,185 | 327,743 | - | 34.1 | 381,740 | Common Stock |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 34.97 per share. | 03 Oct 2022 | 9,904 | 317,839 | - | 35.0 | 346,366 | Common Stock |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2022 | 50,000 | 167,425 | - | - | Stock Option (right to buy) | |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 29.90 per share. | 10 Aug 2022 | 50,000 | 317,839 | - | 29.9 | 1,495,000 | Common Stock |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.39 per share. | 10 Aug 2022 | 50,000 | 367,839 | - | 1.4 | 69,500 | Common Stock |
|
Relay Therapeutics Inc
|
Sekar Kathiresan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jul 2022 | 71,881 | 71,881 | - | - | Stock Option (Right to Buy) | |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 29.90 per share. | 19 Jul 2022 | 50,000 | 317,839 | - | 29.9 | 1,495,000 | Common Stock |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2022 | 50,000 | 217,425 | - | - | Stock Option (right to buy) | |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.39 per share. | 19 Jul 2022 | 50,000 | 367,839 | - | 1.4 | 69,500 | Common Stock |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Jul 2022 | 160,000 | 300,000 | - | - | Stock Option (right to buy) | |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Jul 2022 | 160,000 | 445,308 | - | - | Stock Option (right to buy) | |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Jul 2022 | 160,000 | 240,997 | - | 0 | Common Stock | |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Jul 2022 | 160,000 | 317,839 | - | 0 | Common Stock | |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Jul 2022 | 140,000 | 140,000 | - | - | Stock Option (right to buy) | |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Jul 2022 | 140,000 | 291,988 | - | - | Stock Option (right to buy) | |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Mar 2022 | 69,674 | 605,308 | - | - | Stock Option (right to buy) | |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.87 per share. | 18 Mar 2022 | 69,674 | 477,525 | - | 2.9 | 199,964 | Common Stock |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2022 | 332,000 | 332,000 | - | - | Stock Option (right to buy) | |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.39 per share. | 04 Jan 2022 | 1,870 | 408,406 | - | 1.4 | 2,599 | Common Stock |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 39.90 per share. | 04 Jan 2022 | 1,870 | 406,536 | - | 39.9 | 74,613 | Common Stock |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2022 | 1,870 | 267,425 | - | - | Stock Option (right to buy) | |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2021 | 42,000 | 275,988 | - | - | Stock Option (right to buy) | |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.39 per share. | 27 Dec 2021 | 42,000 | 448,536 | - | 1.4 | 58,380 | Common Stock |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 40.02 per share. | 27 Dec 2021 | 36,443 | 412,093 | - | 40.0 | 1,458,551 | Common Stock |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2021 | 6,693 | 269,295 | - | - | Stock Option (right to buy) | |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 39.90 per share. | 27 Dec 2021 | 6,693 | 406,536 | - | 39.9 | 267,051 | Common Stock |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.39 per share. | 27 Dec 2021 | 6,693 | 413,229 | - | 1.4 | 9,303 | Common Stock |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 41.24 per share. | 27 Dec 2021 | 4,787 | 407,306 | - | 41.2 | 197,431 | Common Stock |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 42.21 per share. | 27 Dec 2021 | 770 | 406,536 | - | 42.2 | 32,502 | Common Stock |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.39 per share. | 22 Dec 2021 | 57,000 | 463,536 | - | 1.4 | 79,230 | Common Stock |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2021 | 57,000 | 317,988 | - | - | Stock Option (right to buy) | |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2021 | 57,000 | 374,988 | - | - | Stock Option (right to buy) | |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 39.90 per share. | 22 Dec 2021 | 57,000 | 406,536 | - | 39.9 | 2,274,300 | Common Stock |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.39 per share. | 22 Dec 2021 | 57,000 | 463,536 | - | 1.4 | 79,230 | Common Stock |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 39.06 per share. | 22 Dec 2021 | 31,139 | 409,805 | - | 39.1 | 1,216,177 | Common Stock |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 38.31 per share. | 22 Dec 2021 | 16,718 | 440,944 | - | 38.3 | 640,532 | Common Stock |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 37.38 per share. | 22 Dec 2021 | 5,874 | 457,662 | - | 37.4 | 219,560 | Common Stock |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 39.78 per share. | 22 Dec 2021 | 3,269 | 406,536 | - | 39.8 | 130,035 | Common Stock |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 53,998 | 53,998 | - | - | Stock Option (right to buy) | |
|
Verve Therapeutics Inc
|
Sekar Kathiresan | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 17 Jun 2021 | 2,500 | 406,536 | - | 19 | 47,500 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges